Meritxell Arenas1, Marina Gascón1, Àngels Rovirosa2, Víctor Hernández3, Francesc Riu4, Iolanda López1, Angel Montero5, Sebastià Sabater6. 1. Radiation Oncology Department, Hospital Universitari Sant Joan de Reus, Institut d'Investigacions Sanitàries Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), Tarragona, Spain. 2. Gynaecologic Cancer Unit, Radiation Oncology Department, Institut Clínic de Malalties Hematològiques i Oncològiques (ICMHO), Hospital Clinic, Barcelona, Spain. 3. Medical Physics and Radiation Protection Department, Hospital Universitari Sant Joan de Reus, IISPV, Spain. 4. Pathology Department, Hospital Universitari Sant Joan de Reus, IISPV, Spain. 5. Radiation Oncology Department, Hospital Ramon y Cajal, Madrid, Spain. 6. Radiation Oncology Department, Complejo Hospitalario Universitario Albacete (CHUA), Spain.
Abstract
AIM: To evaluate the effect of lymphadenectomy and/or radiotherapy on recurrence and survival patterns in endometrial carcinoma (EC) in a radiotherapy reference centre population. MATERIAL AND METHODS: A retrospective population-based review was conducted on 261 patients with stages I-III EC. Univariate and multivariate analyses were carried out. Both recurrence and survival were analysed according to patient age, FIGO stage, tumour size, myometrial invasion, tumour grade, lymphadenectomy, external beam irradiation (EBI), and brachytherapy (BT). RESULTS: Median age: 64.8 years. Median follow-up: 151 months. The following treatments were administered: surgery, 97.32%; lymph-node dissection, 54.4%; radiotherapy, 162 patients (62%) (EBI and BT: 64.1%, BT alone: 30.2%, EBI alone: 5.6%). Twenty-six patients (9.96%) suffered loco-regional recurrence, whilst 27 (10.34%) suffered distant failure. The 5-year overall survival (OS) for all stages was 80.1%. The 5-year disease free survival (DFS) was 92.1% for all patients. The 10-year DFS was 89.9%. The independent significant prognostic factors for a good outcome identified through the multivariate analysis were: age <75 years (p = 0.001); tumour size ≤2 cm (p = 0.003); myometrial invasion ≤50% (p = 0.011); lymphadenectomy (p = 0.02); EBI (p = 0.001); and BT (p = 0.031). Toxicity occurred in 114 of the 162 patients who received radiotherapy (70.5%). The toxicity was mainly acute, and late in only 28.3% (n = 45) of cases. The majority experienced G1-2 toxicity, and only 3% of patients experienced G3 late toxicity (5/162). CONCLUSIONS: Our results suggest that age <75 years, tumour size ≤2 cm, myometrial invasion ≤50%, lymphadenectomy, EBI, and BT, are predictors of a good outcome in EC.
AIM: To evaluate the effect of lymphadenectomy and/or radiotherapy on recurrence and survival patterns in endometrial carcinoma (EC) in a radiotherapy reference centre population. MATERIAL AND METHODS: A retrospective population-based review was conducted on 261 patients with stages I-III EC. Univariate and multivariate analyses were carried out. Both recurrence and survival were analysed according to patient age, FIGO stage, tumour size, myometrial invasion, tumour grade, lymphadenectomy, external beam irradiation (EBI), and brachytherapy (BT). RESULTS: Median age: 64.8 years. Median follow-up: 151 months. The following treatments were administered: surgery, 97.32%; lymph-node dissection, 54.4%; radiotherapy, 162 patients (62%) (EBI and BT: 64.1%, BT alone: 30.2%, EBI alone: 5.6%). Twenty-six patients (9.96%) suffered loco-regional recurrence, whilst 27 (10.34%) suffered distant failure. The 5-year overall survival (OS) for all stages was 80.1%. The 5-year disease free survival (DFS) was 92.1% for all patients. The 10-year DFS was 89.9%. The independent significant prognostic factors for a good outcome identified through the multivariate analysis were: age <75 years (p = 0.001); tumour size ≤2 cm (p = 0.003); myometrial invasion ≤50% (p = 0.011); lymphadenectomy (p = 0.02); EBI (p = 0.001); and BT (p = 0.031). Toxicity occurred in 114 of the 162 patients who received radiotherapy (70.5%). The toxicity was mainly acute, and late in only 28.3% (n = 45) of cases. The majority experienced G1-2 toxicity, and only 3% of patients experienced G3 late toxicity (5/162). CONCLUSIONS: Our results suggest that age <75 years, tumour size ≤2 cm, myometrial invasion ≤50%, lymphadenectomy, EBI, and BT, are predictors of a good outcome in EC.
Authors: D Yalman; Z Ozsaran; Y Anacak; O K Celik; S Ozkök; A Ozsaran; M Hanhan; A Haydaroğlu Journal: Eur J Gynaecol Oncol Date: 2000 Impact factor: 0.196
Authors: S Sabater; Ma M Sevillano; I Andres; R Berenguer; S Machin-Hamalainen; K Müller; M Arenas Journal: Strahlenther Onkol Date: 2013-09-04 Impact factor: 3.621
Authors: H M J Werner; J Trovik; J Marcickiewicz; S Tingulstad; A C Staff; F Amant; H B Salvesen Journal: Gynecol Oncol Date: 2011-11-17 Impact factor: 5.482
Authors: R A Nout; V T H B M Smit; H Putter; I M Jürgenliemk-Schulz; J J Jobsen; L C H W Lutgens; E M van der Steen-Banasik; J W M Mens; A Slot; M C Stenfert Kroese; B N F M van Bunningen; A C Ansink; W L J van Putten; C L Creutzberg Journal: Lancet Date: 2010-03-06 Impact factor: 79.321
Authors: M S Carey; G J O'Connell; C R Johanson; M D Goodyear; K J Murphy; D M Daya; A Schepansky; A Peloquin; B J Lumsden Journal: Gynecol Oncol Date: 1995-05 Impact factor: 5.482
Authors: Paweł Cisek; Dariusz Kieszko; Izabela Kordzińska-Cisek; Elżbieta Kutarska; Ludmiła Grzybowska-Szatkowska Journal: Biomed Res Int Date: 2018-02-21 Impact factor: 3.411